W Michael Kavanaugh

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Top Venues

Cancer research

Molecular cancer therapeutics

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Shweta Singh, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, Leyu Wang, Michael Krimm, Ken Wong, Jason Sagert, Kimberly Tipton, Stephen J Moore, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Shouchun Liu, Olga Vasiljeva, Yingchun Li, Tracy Henriques, Ilaria Badagnani, Shawn Jeffries, Siew Schleyer, Rob Leanna, Claus Krebber, Sridhar Viswanathan, Luc Desnoyers, Jonathan Terrett, Marcia Belvin, Susan E Morgan-Lappe, W Michael Kavanaugh, Jennifer Richardson
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Molecular cancer therapeutics 21 (8) (2022)
Leila M Boustany, Sherry L LaPorte, Laurie Wong, Clayton White, Veena Vinod, Joel Shen, Wendy Yu, David Koditek, Michael B Winter, Stephen J Moore, Li Mei, Linnea Diep, Yuanhui Huang, Shouchun Liu, Olga Vasiljeva, Jim West, Jennifer Richardson, Bryan Irving, Marcia Belvin, W Michael Kavanaugh
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Cancer research 82 (22) (2022)
Hikmat H Assi, Chihunt Wong, Kimberly A Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W West, Jennifer H Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W Michael Kavanaugh
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. Cancer immunology research 9 (12) (2021)